Melanotan II: What It Is Studied Alongside

Melanotan II (also referred to as MT-II) is a synthetic cyclic peptide analogue belonging to the melanocortin hormone family, and it is unlicensed in the jurisdictions covered by the available literature [1]. The evidence block does not supply a sequence, molecular formula, or molecular weight for the compound, so none is stated here. The work on this molecule centres on the melanocortin receptor family — a group of Class A G protein-coupled receptors with roles spanning pigmentation, steroidogenesis, and energy homeostasis — and Melanotan II is characterised in that literature as a non-selective melanocortin receptor agonist [1][6].

Because the receptor family is expressed both centrally and peripherally, the studies that use Melanotan II do not sit in a single field. They appear in dermatology case reporting, in a registered phototherapy-adjunct trial, in analytical chemistry work on seized samples, and in rodent behavioural pharmacology. The sections below set out what each of those lines of work actually examined, and where the evidence is animal-only or in vitro.

Research Studies

Melanotan II and melanocortin 1 receptor signalling in melanocytes

The mechanism most consistently described for Melanotan II is activation of melanocortin 1 receptors on melanocytes, which stimulates eumelanin production and produces skin pigmentation independently of sun exposure [1]. This is the receptor-level account that the clinical and case literature returns to, and it is the reason the compound appears in pigmentation research rather than in work on the other melanocortin subtypes. The broader tool-compound literature notes that five melanocortin receptor subtypes exist and that MC2R is set apart from the others in the family [6]; Melanotan II's documented activity in the pigmentation context is attributed to MC1R rather than to that subtype [1].

Melanotan II and oral mucosa in a 64-day self-administration case

A case report followed a patient for three months after the patient self-administered Melanotan II injections over a period of 64 days with the aim of deepening tanning [1]. On initial intraoral examination, brown pigmentation was observed [1]. This is a single-patient observational report, not a controlled study, and it describes an adverse finding in one individual rather than an established effect size. It is included here because it is one of the few sources that documents a tissue-level observation in a human following Melanotan II exposure.

Melanotan II and NB-UVB phototherapy in stable nonsegmental vitiligo

A registered randomised Phase 2 clinical trial evaluated investigational Melanotan II as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo [2]. The record describes the design and the population — adults with stable nonsegmental vitiligo — and positions the compound alongside an established phototherapy protocol rather than as a standalone intervention [2]. No results are reported in the evidence block, so no efficacy claim is made here.

Melanotan II nasal spray and anterior maxillary mass

A published case describes a 22-year-old female who developed a mass in the anterior maxilla after using a Melanotan II nasal spray for tanning purposes; the spray contained a synthetic analogue of melanocyte-stimulating hormone [3]. The report notes that Melanotan II is unlicensed and that its sale is illegal in the jurisdiction concerned [3]. This is a single case and does not establish causation, but it is part of the record on non-injection routes of exposure.

Melanotan II and chronic unpredictable stress in male rats

In a rodent model of chronic unpredictable stress, the ACTH(4-10) synthetic analogues Semax and Melanotan II were examined for antidepressant-like and antistress effects in male rats [4]. The rationale given in that work concerns the hypothalamic-pituitary-adrenal axis, whose hyperactivity is described as playing an important role in the pathogenesis of depression, and the limitations of current antidepressant therapy [4]. This evidence is animal-only. No human data on mood or stress endpoints are supplied by the evidence block, and none is claimed here.

Melanotan II and analytical identification in seized samples

Analytical work submitted samples including two vials with a pharmaceutical appearance for identification, using HPLC-DAD, UHPLC-TOF-MS, and/or UPLC-MS-MS, and described the characteristics observed during analysis of the powder contained in a vial [5]. This line of work is about detection and characterisation of the material as it appears in submitted samples, not about biological activity. It is relevant to the page because it shows the compound being studied alongside instrumental methods rather than alongside a receptor or a tissue.

Melanotan II and melanocortin receptor tool-compound characterisation

The melanocortin receptors are described as a centrally and peripherally expressed family of Class A GPCRs with physiological roles including pigmentation, steroidogenesis, and energy homeostasis, and with functions yet to be fully characterised [6]. Melanotan II appears in this literature as one of the compounds used to probe that receptor family [6]. This is reference material for the receptor pharmacology rather than a study of Melanotan II in a specific tissue, and it is cited here to place the compound within the melanocortin receptor field.

Melanotan II and the limits of the current evidence base

Across the sources available, the human material is limited to case reporting and a registered trial record without reported results [1][2][3]. The controlled experimental work is in male rats [4], and the remaining sources are analytical or pharmacological reference material [5][6]. Where a finding comes from a single patient or from an animal model, it is labelled as such above. No human dose, protocol, or outcome is stated anywhere on this page, because the evidence block does not supply one.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing on this page is a recommendation, a protocol, or a substitute for professional advice.

Sources

• [1] Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report — https://europepmc.org/article/PMC/PMC12942211
• [2] Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo — https://clinicaltrials.gov/study/NCT07437560
• [3] Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? — https://pubmed.ncbi.nlm.nih.gov/40210573/
• [4] Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress — https://pubmed.ncbi.nlm.nih.gov/39442746/
• [5] Barbie drug identification: Not a child's play — https://pubmed.ncbi.nlm.nih.gov/39302005/
• [6] Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs) — https://europepmc.org/article/PMC/PMC11406693